Ross Merkin

Attending Physician, Medical Oncology, Center for Head and Neck Cancer

Massachusetts General Hospital

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Ross Merkin is an Attending Physician specializing in Medical Oncology at Massachusetts General Hospital, USA. His research focuses on immuno-oncology, particularly in the context of renal cell carcinoma and its metastases, as well as the impacts of immune checkpoint inhibitors on T-cell dynamics. He has also contributed to the understanding of treatment strategies for non-small cell lung cancer and the effects of the COVID-19 pandemic on medical residency programs.

Articles (5)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2020

Collaborators (1)

David Braun

Assistant Professor, Principal Investigator

Yale University Yale Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ross Merkin

Research Interests

Explore related searches

Contact this professor

About

Articles (5)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases

ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis.

Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.

Internal Medicine Resident Work Absence During the COVID-19 Pandemic at a Large Academic Medical Center in New York City.

Collaborators (1)

David Braun

Make your next move.